Addressing the Innovation Gap
Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function and offers great promise in the prevention and treatment of many serious diseases.
However, there are a number of technical and regulatory barriers faced by researchers, industry and healthcare professionals in their quest to translate regenerative therapies into the clinic. Regener8 was established to help overcome these barriers.
Regener8 translates research in regenerative medicine into commercial products and clinical benefits. Hosted by the University of Leeds and working collaboratively with the leading research-intensive universities of the north of England and beyond, Regener8 bridges the early stage innovation gap creating commercial value from academic knowledge. Regener8 is well positioned to connect and influence the UK national regenerative medicine landscape, especially through its strategic alliance with the Medical Technologies IKC. We have a membership base of over 330 academics and over 260 industry partners.
Regener8 works at the interface of industry, academia and clinical application and seeks to create collaborative opportunities for key players in the community to be brought together to exchange information and build partnerships. There is a particular need to support the emergent regenerative medicine industry in the UK (the majority of which are SMEs) and provide them with opportunities for access to, and collaboration with, leading academics as well as leading providers from the supply chain and support base.
Regener8 has a national profile within the UK and organises an annual conference attracting around 150 delegates. We also focus on raising the translational awareness and capability of academic researchers, and support a programme of early stage translational projects involving industrial-, clinical- and university-based researchers
Regener8’s mission is to:
- Progress the commercial development of regenerative therapies and devices
- Accelerate the development of biomaterials and matrices as acellular scaffolds
- Advance the technologies to support cell therapies, particularly those using minimally-manipulated stem cells
- Move RegenMed therapies into the clinic through the development of clinical delivery technologies
- Connect and influence the RegenMed community
Regener8 works to overcome barriers to the translation of regenerative medicine therapies, by providing support to our members in areas such as:
- Preclinical evaluation
- Safety and efficacy testing
- Clinical validation
- Scale-up and Quality Management
- Supply/support chain mapping
- Health economics and market access
- Clinical trials
- Commercial viability
- Reimbursement and adoption
A strong track record
During our first phase (2007 to 2011):
- Created and developed the Regener8 network
- Created 22 new jobs
- Catalysed a portfolio of multi-partner innovation projects, leveraging £18 million of direct and £35 million of indirect investment.
- Assisted over 100 companies in innovation and translation activities
In our current phase (2012 to present):
We have continued to support our industry, academic and clinical members in the RegenMed community. Operationally, we have consolidated our links with the Medical Technologies Innovation and Knowledge Centre (IKC) to form a strategic alliance of the two organisations – funded by Innovate UK, EPSRC and BBSRC. This has enabled us to improve our integration with the wider UK medical technologies community whilst retaining our focus on the translation of regenerative technologies into therapies.
We will continue to pursue our key strategic objectives of:
- Connecting the national landscape – Regener8 has a very strong membership base in both industry and academic settings and knowledge of publically-funded support infrastructure and this will be used to further develop our national role and national platform.
- International partnership developments: our current focus is on the identification of potential strategic partner organisations in Singapore, China and North America.
- Delivery and oversight of the N8 Proof of Concept projects and facilitation of their pathway to commercialisation.
- Development of academic innovation and translation capability.
- Widening engagement of Early Career Researchers (ECRs) through the development of a dedicated ECR network.
- Continued support for Regener8’s membership base and provision of information – through our website and Annual Conference as well as through networking opportunities.
- Stronger N8 and UK-wide collaborations – gained from N8 experts working together and the provision of this pool of expertise to UK regenerative medicine companies.
Leeds will deliver a landmark report on the UK’s MedTech landscape and the role of the North within it, as part of the second wave of Science & Innovation Audits.
Executive Director: Professor John Fisher
(Professor of Mechanical Engineering and Director of the Institute for Medical and Biological Engineering, University of Leeds)
Operations Director: Dr Mike Raxworthy
Tel: +44 (0) 113 343 0933